Search Follow us


Adocia is a clinical-stage biotech company that leverages its proprietary BioChaperone (BC) platform technology to generate improved formulations of approved products for diabetes. Its most advanced asset is BC Lispro, an ultra-fast formulation of insulin lispro ready to enter Phase III trials, after Lilly terminated a partnership agreement. Adocia has recently started a clinical study with BC Pramlintide Insulin and plans to start two more clinical trials in 2018 with its hormonal products, BC Glucagon GLP-1 and BC GLP-2. End 2017 net cash was €27.5m.

Continue reading

This version is programmatically created by Responsive Labs and qualified in its entirety to the original PDF.

Powered by Responsive Labs